Both inflammation and hyperlipidemia contribute to cardiovascular disease. However in patients receiving statin therapy the relative contributions of inflammation and hyperlipidemia to future CV risk can change. As a result, this has implications on adjunctive therapy choice.
In this episode, Dr. Chadi Alraies discusses a recent study that evaluated high sensitivity CRP and LDL-C as predictors of cardiovascular event risk in patients on statin therapy.
Original article: Ridker PM et al. Lancet. 2023 Mar 3;S0140-6736(23)00215-5.